Langendonk M, Smit N, Plattel W, Diepstra A, Meerten T, Visser L. Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma. Int J Mol Sci. 2022;23: pubmed publisher

Pag xe1 n A, Lee L, Edwards Hicks J, Moens C, Tobin D, Busch Nentwich E, et al. mTOR-regulated mitochondrial metabolism limits mycobacterium-induced cytotoxicity. Cell. 2022;185:3720-3738.e13 pubmed publisher

Surman D, Xu Y, Lee M, Trepel J, Brown K, Ramineni M, et al. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling. Mol Cancer Ther. 2021;20:1469-1480 pubmed publisher

Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Mayerh xf6 fer M, et al. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica. 2021;106:2251-2256 pubmed publisher

Dhimolea E, de Matos Simoes R, Kansara D, Al Khafaji A, Bouyssou J, Weng X, et al. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell. 2021;39:240-256.e11 pubmed publisher

de Jong M, Langendonk M, Reitsma B, Herbers P, Nijland M, Huls G, et al. WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage. Cancers (Basel). 2019;11: pubmed publisher

Seyfried F, Demir S, Hörl R, Stirnweiß F, Ryan J, Scheffold A, et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis. 2019;10:571 pubmed publisher

Dang E, McDonald J, Russell D, Cyster J. Oxysterol Restraint of Cholesterol Synthesis Prevents AIM2 Inflammasome Activation. Cell. 2017;171:1057-1071.e11 pubmed publisher